Estrella Immunopharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ESLA Nasdaq 2834 www.estrellabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Estrella Immunopharma, Inc.

ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial - Aug 26th, 2026 6:42 am
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - Aug 11th, 2026 6:00 am
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - Aug 3rd, 2026 6:00 am
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - Jul 29th, 2026 6:00 am
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma - Jul 24th, 2026 6:00 am
ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma? - Jul 14th, 2026 4:22 am
ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T - Mar 18th, 2026 3:20 am
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL - Feb 9th, 2026 7:02 am
Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either? - Nov 4th, 2025 10:13 am